Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines

Journal of Infectious Diseases

Volumn 200, Issue 9, 2009, Pages 1452-1455

  Rowhani Rahbar, Ali ^a   Carter, Joseph J ^c   Hawes, Stephen E ^a   Hughes, James P ^b   Weiss, Noel S ^a   Galloway, Denise A ^c   Koutsky, Laura A ^a  

^a Health Services and Epidemiology   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PLACEBO; WART VIRUS VACCINE;

ADULT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SENSITIVITY ANALYSIS; VIRUS INFECTION;

ADULT; ANTIBODIES, VIRAL; EXUDATES AND TRANSUDATES; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MOUTH MUCOSA; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; ROC CURVE;

EID: 72849123058     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/606026     Document Type: Article

References (15)

1. George JR, Fitchen JH. Future applications of oral fluid specimen technology. Am J Med 1997; 102:21-25
2. Cordeiro ML, Turpin CS, McAdams SA. A comparative study of saliva and OraSure oral fluid. Ann NY Acad Sci 1993; 694:330-331 (Pubitemid 23298269)
3. Buchinsky FJ, Carter JJ, Wipf GC, Hughes JP, Koutsky LA, Galloway DA. Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women. J Clin Virol 2006; 35:450-453
4. Cameron JE, Snowhite IV, Chaturvedi AK, Hagensee ME. Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals. Clin Diagn Lab Immunol 2003; 10:431-438
5. Marais DJ, Best JM, Rose RC, et al. Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia. J Med Virol 2001;65: 149-154 (Pubitemid 32727020) (Pubitemid 32727020)
6. Passmore JA, Marais DJ, Sampson C, et al. Cervicovaginal, oral, and serum IgG and IgA responses to human papillomavirus type 16 in women with cervical intraepithelial neoplasia. J Med Virol 2007; 79:1375-1380
7. Marais DJ, Sampson C, Jeftha A, et al. More men than women make mucosal IgA antibodies to Human papillomavirus type 16 (HPV-16) and HPV-18: a study of oral HPV and oral HPV antibodies in a normal healthy population. BMC Infect Dis 2006; 6:95. (Pubitemid 44144654) (Pubitemid 44144654)
8. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-1255
9. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107:18-27. (Pubitemid 43755499) (Pubitemid 43755499)
10. Villa LL, Ault KA, Giuliano AR, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24:5571-5583
11. Waterboer T, Sehr P, Michael KM, et al. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 2005; 51:1845-1853 (Pubitemid 41368175) (Pubitemid 41368175)
12. Waterboer T, Sehr P, Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 2006; 309:200-204 (Pubitemid 43190816)
13. Olsson SE, Villa LL, Costa RL, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25:4931-4939
14. Cameron SO, Carman WF. The use of the OraSure collection device for hepatitis virus testing in health care settings. J Clin Virol 2005; 34(Suppl 1):S22-8.
15. Nokes DJ, Enquselassie F, Nigatu W, et al. Has oral fluid the potential to replace serum for the evaluation of population immunity levels? A study of measles, rubella and hepatitis B in rural Ethiopia. Bull World Health Organ 2001; 79:588-595 (Pubitemid 32678444)